Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 95 | -104 | -2,629 | -2,938 | -328 |
| Depreciation Amortization | 61 | 30 | 108 | 79 | 50 |
| Accounts receivable | -3 | -113 | 651 | 506 | 354 |
| Accounts payable and accrued liabilities | -458 | 55 | -381 | -365 | -111 |
| Other Working Capital | -322 | 4 | 118 | 106 | -1 |
| Other Operating Activity | -82 | 90 | 311 | 1,572 | -104 |
| Operating Cash Flow | $-709 | $-37 | $-1,822 | $-1,040 | $-140 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -24 | -22 | -149 | -149 | -15 |
| Purchase Of Investment | -265 | -174 | -321 | -296 | -13 |
| Sale Of Investment | 298 | 211 | 26 | 27 | N/A |
| Other Investing Activity | 58 | -12 | -1,350 | 49 | 20 |
| Investing Cash Flow | $67 | $4 | $-1,794 | $-369 | $-8 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 5,750 | 5,750 | N/A |
| Other Financing Activity | 202 | 27 | 525 | -7 | -4 |
| Financing Cash Flow | $202 | $27 | $6,275 | $5,743 | $-4 |
| Exchange Rate Effect | -115 | -72 | -260 | -307 | -208 |
| Beginning Cash Position | 4,518 | 4,518 | 2,119 | 2,119 | 2,119 |
| End Cash Position | 3,962 | 4,439 | 4,518 | 6,147 | 1,759 |
| Net Cash Flow | $-556 | $-79 | $2,399 | $4,028 | $-360 |
| Free Cash Flow | |||||
| Operating Cash Flow | -709 | -37 | -1,822 | -1,040 | -140 |
| Capital Expenditure | -24 | -22 | -149 | -149 | -15 |
| Free Cash Flow | -733 | -59 | -1,972 | -1,188 | -155 |